This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pediatrix Medical Group (MD) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Pediatrix Medical Group (MD) delivered earnings and revenue surprises of 4.55% and 0.75%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Organon (OGN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Organon (OGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Pediatrix Medical Group (MD) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Pediatrix Medical Group (MD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pediatrix (MD) Q4 Earnings miss on High Operating Expenses
by Zacks Equity Research
Pediatrix (MD) anticipates 2023 adjusted EBITDA to be within $235-$245 million.
Pediatrix Medical Group (MD) Lags Q4 Earnings Estimates
by Zacks Equity Research
Pediatrix Medical Group (MD) delivered earnings and revenue surprises of -4.08% and 2.43%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Teladoc (TDOC) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Teladoc (TDOC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pediatrix Medical (MD) to Post Q4 Earnings: What to Expect
by Zacks Equity Research
Pediatrix Medical's (MD) fourth-quarter results are likely to reflect higher operating expenses and patient volume growth.
Earnings Preview: Pediatrix Medical Group (MD) Q4 Earnings Expected to Decline
by Zacks Equity Research
Pediatrix Medical Group (MD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for December 23rd
by Zacks Equity Research
SGRP, LFCR and MD have been added to the Zacks Rank #5 (Strong Sell) List on December 23, 2022.
Pediatrix (MD) Down 19% Since Q3 Earnings & Revenue Miss
by Zacks Equity Research
Pediatrix's (MD) Q3 results reflect volume constraints and an elevated expense level. Adjusted EBITDA is now expected within $240-$245 million, down from the earlier view of $260-$270 million.
Pediatrix Medical Group (MD) Misses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Pediatrix Medical Group (MD) delivered earnings and revenue surprises of -24.53% and 4.50%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Can Humana (HUM) Sustain Its Earnings Beat Streak in Q3?
by Zacks Equity Research
Humana's (HUM) Q3 results are expected to reflect growing premiums, attributable to its Medicare Advantage and Medicaid businesses. However, elevated marketing costs might have strained its margins.
NovoCure (NVCR) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
NovoCure (NVCR) delivered earnings and revenue surprises of 16.67% and 2.85%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
3 Healthcare Stocks Set to Outshine Q3 Earnings Estimates
by Kaibalya Pravo Dey
Recovering volumes, improved admissions, growing health awareness and wide utilization of technologies in the third quarter are expected to have aided healthcare stocks like Humana (HUM), Teladoc (TDOC) and Pediatrix Medical (MD).
Can Rising Visits Help Teladoc (TDOC) Beat on Earnings in Q3?
by Zacks Equity Research
The third-quarter results of Teladoc (TDOC) are likely to reflect a rise in Access Fees and Visit Fee revenues.
Earnings Preview: Avantor, Inc. (AVTR) Q3 Earnings Expected to Decline
by Zacks Equity Research
Avantor, Inc. (AVTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pediatrix Medical Group (MD) to Report Q3 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Pediatrix Medical Group (MD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strength Seen in Icon PLC (ICLR): Can Its 5.3% Jump Turn into More Strength?
by Zacks Equity Research
Icon PLC (ICLR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Elevance Health (ELV) to Post Q3 Earnings: A Beat in the Cards?
by Zacks Equity Research
Elevance Health's (ELV) third-quarter results are likely to reflect improved premiums and net investment income.
Here's Why Pediatrix Medical Group (MD) is a Strong Value Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
MD or GDRX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
MD vs. GDRX: Which Stock Is the Better Value Option?
The Beauty Health Company (SKIN) Stock Jumps 11.4%: Will It Continue to Soar?
by Zacks Equity Research
The Beauty Health Company (SKIN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Pediatrix (MD) Up 8% Since Q2 Earnings Release, Revenues Up Y/Y
by Zacks Equity Research
Pediatrix's (MD) second-quarter results reflect growth in patient volumes. Adjusted EBITDA is expected within $260-$270 million for 2022.
Mednax (MD) Q2 Earnings Match Estimates
by Zacks Equity Research
Mednax (MD) delivered earnings and revenue surprises of 0% and 1.34%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Mednax (MD) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Mednax (MD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.